Moderate SLE Without Renal Involvement: Next-Line Treatment When Initial Therapy Has Not Achieved Remission
This protocol addresses patients with moderate systemic lupus erythematosus without renal involvement whose disease activity has not reached remission or low disease activity despite a full course of first-line therapy.
Clinical Scenario
Moderate SLE without renal involvement is characterised by moderate-to-severe arthritis, rash covering 9–18% of body surface area, platelet count 20–50 × 10⁹/L, serositis, a SLEDAI score of 7–12, and at least two BILAG B manifestations.
First-Line Treatment — Targets Not Met
Initial management included hydroxychloroquine, corticosteroid pulses with methylprednisolone followed by oral prednisone taper, and the addition of one or more of methotrexate, azathioprine, or mycophenolate, with or without belimumab or anifrolumab. This line aimed for a SLEDAI score of 0 (remission) or SLEDAI ≤4 (low disease activity state) — goals that were not achieved, indicating the need for escalation.
Next-Line Approach
When first-line targets are not met, escalation to a more potent immunosuppressive strategy is warranted — the specific agents and how they are applied are detailed in the full structured protocol.
Treatment Goals
SLEDAI score of 0 (remission) or SLEDAI ≤4 (low disease activity state).
References
DOI: 10.1136/ard-2023-224762
Moderate disease: moderate–severe arthritis (‘RA-like’; rash 9%–18% BSA; PLTs 20–50×10⁹/L; serositis; SLEDAI 7–12; ≥2 BILAG B manifestations).
In patients with organ-threatening or life-threatening disease, intravenous cyclophosphamide (2b/C) should be considered; in refractory cases, rituximab (2b/C) may be considered.
View source ↗